Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors

Evotec and Plectonic announced a collaboration to validate Evotec’s BiTco costimulatory CD2 bispecifics platform combined with Plectonic’s LOGIBODY® logic-gated DNA-protein immunotherapy (LOGIBODY® BiTco). The effort targets improved T cell activation by engaging a costimulatory signaling pathway. With no financial terms or clinical milestones disclosed, near-term impact is likely limited.